BridgeBio Oncology Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $10.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $10.92M, a 18.90% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$31.00K, a 101.32% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-06-30 was $9.19M.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-03-31 was $2.34M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|
| 2026-06-30 | $10.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $10.89M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$31.00K 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | $17.68M POS AM · filed 2026-04-30 | ||
| 2025-06-30 | $9.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $11.53M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $2.34M 10-Q · filed 2026-05-12 | ||
| 2024-12-31 | $4.90M POS AM · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |